Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Clin Chem Lab Med ; 51(8): 1637-42, 2013 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-23443266

RESUMEN

BACKGROUND: A mobile clinical pathology laboratory (MoLab) was designed, outfitted and evaluated to improve the turnaround time (TAT) of laboratory tests performed in patients who receive follow-up care at home. METHODS: Full blood counts (FBCs), basic clinical biochemistry tests on blood and urine, and basic coagulation and blood gases were measured using bench-top laboratory analyzers to perform point-of-care tests in a mobile setting. The quality of the results was evaluated on the instruments both while the vehicle was at rest and following movement during the course of routine activity. RESULTS: The equivalence of the values produced by the point-of-care testing (POCT) and central laboratory (CL) measurement procedures was demonstrated and remained stable after movement in city traffic. The TATs ranged from a few minutes for FBCs to <20 min for extended clinical biochemistry tests. CONCLUSIONS: During the first 6 months of activity, the MoLab assured the provision of laboratory results for home care patients in a matter of minutes. This approach not only allowed for real-time modifications in therapy but also reduced the number of second visits by the home care medical team. Point-of-care tests performed on the MoLab were significantly more expensive than the same tests performed in the CL. However, the savings in patient hospitalization expenses and the reduced costs resulting from fewer second daily visits completely offset the costs of using the MoLab during the first 6-month pilot phase.


Asunto(s)
Técnicas de Laboratorio Clínico/instrumentación , Técnicas de Laboratorio Clínico/normas , Trasplante de Células Madre Hematopoyéticas/instrumentación , Trasplante de Células Madre Hematopoyéticas/normas , Servicios de Atención de Salud a Domicilio/normas , Niño , Técnicas de Laboratorio Clínico/economía , Trasplante de Células Madre Hematopoyéticas/economía , Servicios de Atención de Salud a Domicilio/economía , Humanos , Control de Calidad , Factores de Tiempo
2.
Immunol Lett ; 149(1-2): 62-7, 2013 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-23206888

RESUMEN

The modifications of the subsets of circulating lymphocytes were evaluated in a group of patients with COPD undergoing treatment with a polyvalent mechanical bacterial lysate (PMBL), a drug that is able to significantly modify the natural history of these patients. Using multicolor immune-florescence and flow cytometry, T, B subsets and NK cells were extensively studied both in the group of treated patients and in a disease and age matched controls. Despite the age, in treated patients, T and NK cells were significantly increased in numbers of circulating cells, but not in percentages, while B cells remained unmodified. CD3+4+T cells were increased in treated patients, while CD3+CD8T cells were unmodified by the treatment. Activated T cells were increased but Treg, resulted reduced both in percentage than in absolute numbers. Transitional B cells resulted increased (in percentage and in absolute numbers) in their late maturation step (T3), while only early Naïve B cells were increased by the treatment, while other naïve subpopulations were unmodified. Memory B cells were reduced in percentage (but remained unmodified as absolute numbers), while the most immature form of memory B cells was significantly increased. Finally, both switch memory B cells and plasma cells resulted unmodified by the PMBL treatment. These results clearly indicated that the administration of the PMBL, even in elderly patients with COPD, was able to induce a significant immune-stimulation and these results, at cellular level, clearly support the evidence that the mechanism of action of PMBL is strictly related to a direct effect on immune-competent cells.


Asunto(s)
Adyuvantes Inmunológicos/administración & dosificación , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD8-positivos/inmunología , Extractos Celulares/administración & dosificación , Células Asesinas Naturales/inmunología , Células Plasmáticas/inmunología , Enfermedad Pulmonar Obstructiva Crónica/inmunología , Adulto , Anciano , Linfocitos T CD4-Positivos/metabolismo , Linfocitos T CD8-positivos/metabolismo , Método Doble Ciego , Femenino , Humanos , Memoria Inmunológica/efectos de los fármacos , Células Asesinas Naturales/metabolismo , Masculino , Persona de Mediana Edad , Células Plasmáticas/metabolismo , Enfermedad Pulmonar Obstructiva Crónica/sangre
3.
Pediatr Allergy Immunol ; 23(5): 433-40, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-22103266

RESUMEN

BACKGROUND: It is well known that allergy evolves at clinical level from the birth to adulthood, and this has been clearly demonstrated also at a level of sensitization. However, little information is available on the evolution of the IgE repertoire directed to single allergenic components. In this cross-sectional, observational study, the evolution of the IgE repertoire was analysed at component level. METHODS: Serum samples from 901 allergic patients, stratified in 6 groups according to age, were analysed by ImmunoCAP ISAC, a microarray chip that allows to identify the presence of specific IgE towards 103 different allergen components. Total IgE were also evaluated. RESULTS: The behaviour of total IgE according to age strictly paralleled that of the sum of specific IgE directed to molecular components. As expected, food-related components (in particular those of milk and egg) were the most frequently recognized in the earliest ages, whereas specific IgE to plant allergens appeared invariably later. Nonetheless, IgE specific to mite components was the most represented in all age classes. Of note, specific IgE against cross-reacting allergens was virtually absent in the first years and tended to appear only after the age of 6. CONCLUSION: Despite this was not a study performed on a cohort of patients followed up from birth to adolescence, the molecular patterns of allergen recognition resulted modified according to age. These findings may support, at molecular level, the clinical features of the allergic march.


Asunto(s)
Alérgenos/inmunología , Hipersensibilidad/inmunología , Inmunoglobulina E/inmunología , Adolescente , Adulto , Factores de Edad , Niño , Preescolar , Reacciones Cruzadas , Estudios Transversales , Femenino , Humanos , Hipersensibilidad/diagnóstico , Inmunoglobulina E/sangre , Lactante , Recién Nacido , Masculino , Análisis por Micromatrices , Patología Molecular , Adulto Joven
4.
Immunol Lett ; 138(1): 86-91, 2011 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-21453728

RESUMEN

Dendritic cells (DCs), following an optimal maturation, are able to drive an efficient immune-response. For this, both co-stimulatory molecules (CD80 and CD86), activation molecules (CD83) and peptide presenting molecules (HLA) are over-expressed. The in vitro treatment of immature DC with fragments of bacterial strains, obtained by using a mechanical lysis as well as with bacterial-derived molecules (such as lipopolysaccharide and protido-glycan), induced the maturation of DCs and the secretion of a panel of cytokines and chemokines. Of note, ex vivo treated circulating DCs and plasmacytoid DCs were also activated by these bacterial bodies. However, while the particulate fraction of single bacterial strains or soluble bacterial-derived molecules induced a sub-optimal maturation (as evaluated by the expression of an activating phenotype on DCs and the amount of cytokine secretion), the addition of the mixture of the particulate fractions of the different bacterial strains was able to mediate an optimal maturation. These results were also confirmed by using the secretion of both cytokines and chemokines as markers of DC activation. All these findings suggest that the particulate fraction of bacterial lysate mixtures, because of their ability to interact with different surface structures, might be exploited not only as an immunogen, but also as an adjuvant treatment to boost an immune-response to poorly "antigenic" proteins, such as cancer antigens or allergens.


Asunto(s)
Bacterias/inmunología , Extractos Celulares/inmunología , Células Dendríticas/inmunología , Fenotipo , Antígenos de Superficie/metabolismo , Diferenciación Celular/inmunología , Citocinas/metabolismo , Células Dendríticas/citología , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA